Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapid Restart of B/F/TAF in HIV-1 Patients Returning to Care (REINITIATE)
NCT07476339Phase 4Recruiting
- Sponsor
- CAN Community Health
- Start
- Jun 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
A Phase 4 trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus type 1 infection (HIV-1), sponsored by CAN Community Health. Started Jun 2026; status: recruiting.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT07476339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07476339.